Loading
Milestone Scientific Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 20 Dec 2022.
Milestone Scientific Inc.: what insiders have been doing
This page follows insider dealings at Milestone Scientific Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. Over the twelve months to 18 October 2026, 2 filings were filed, from 1 insider.
The flow runs one way only: 2 sales worth €15k, from 1 insider, and no purchase. The largest single trade was a sale of €9,344 by BP4 S.r.l., published on 23 October 2025.
Compared with its exchange (5,816 companies, median 19 filings), a count of 2 filings is below the norm. Our records for Milestone Scientific Inc. go back to 2021, with 7 purchases and 48 sales on the open market in total. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 9.0 m USD and net income of -5.7 m USD.
Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Anixa Biosciences Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
98
Thresholds
n/a
Buy Volume
€154,430
7 ops. · all time
Sell Volume
€706,898
48 ops. · all time
Who traded when
BuySaleBP4 S.r.l.18 sales
Michael McGeehan1 sale
Since the insiders bought
- +35.5%Entry US$0.62 · Close at T+365 US$0.84
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 21,447 of 24,148 companies
23.5
score / 100
Value17
Quality30
FCF yld-6.9%
Earn yld-13%
EV/EBITDA·
ROE-135%
Gross mgn71%
Net mgn-64%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.48
Analyst consensus
2 analysts1.50/5
US$1.00Target US$1.00(+108%)US$1.00
Income statement
RevenueUS$9M
Gross profitUS$6.4M71% margin
EBITDA-US$5.5M-61% margin
Net income-US$5.7M-51.3% margin
Valuation
PER (forward)-13.7x
P/Book17.2x
Beta1.05
Balance sheet & cash
Market capUS$42.6M
Total debtUS$1M
Free Cash Flow-US$2.9M
Debt / Equity43%
Profitability & ownership
ROE-135.4%
ROA-33.2%
% insiders16.1%
% institutions5.2%
Last declaration on 29 October 2025
Declarations98 total
14,427 shares@ US$0.44972.6% of flowCommon Stock, Par Value $0.001SEC:0001493152-25-020077:0
24,034 shares@ US$0.45274.4% of flowCommon Stock, Par Value $0.001SEC:0001493152-25-019114:0
10,158 shares@ US$0.55012.3% of flowCommon Stock, Par Value $0.001SEC:0001493152-25-018483:0
10,000 shares@ US$0.451.8% of flowCommon Stock, Par Value $0.001SEC:0001437749-25-030794:0
9,210 shares@ US$0.44911.7% of flowCommon Stock, Par Value $0.001SEC:0001437749-25-030744:0
10,000 shares@ US$0.5942.4% of flowCommon Stock, Par Value $0.001SEC:0001437749-25-029170:0
10,000 shares@ US$0.642.6% of flowCommon Stock, Par Value $0.001SEC:0001437749-25-023233:0
50,853 shares@ US$0.669813.5% of flowCommon Stock, Par Value $0.001SEC:0001437749-25-022536:0
5,933 shares@ US$0.86042.1% of flowCommon Stock, Par Value $0.001SEC:0001437749-25-022001:0
10,056 shares@ US$0.89513.6% of flowCommon Stock, Par Value $0.001SEC:0001437749-25-020823:0
23,797 shares@ US$0.9028.7% of flowCommon Stock, Par Value $0.001SEC:0001437749-25-020381:0
20,266 shares@ US$0.9057.5% of flowCommon Stock, Par Value $0.001SEC:0001437749-25-020077:0
26,855 shares@ US$0.910410.0% of flowCommon Stock, Par Value $0.001SEC:0001437749-25-019933:0
60,200 shares@ US$0.901422.2% of flowCommon Stock, Par Value $0.001SEC:0001437749-25-019933:1
8,000 shares@ US$0.93693.1% of flowCommon Stock, Par Value $0.001SEC:0001437749-25-019682:0
12,118 shares@ US$0.93074.6% of flowCommon Stock, Par Value $0.001SEC:0001437749-25-019286:0
3,361 shares@ US$0.961.3% of flowCommon Stock, Par Value $0.001SEC:0001437749-25-019021:1
14,256 shares@ US$0.965.7% of flowCommon Stock, Par Value $0.001SEC:0001437749-25-019021:0
20,000 shares@ US$0.77666.2% of flowCommon Stock, Par Value $0.001SEC:0001437749-24-038113:0
107,984 shares@ US$0.937.5% of flowCommon Stock, Par Value $0.001SEC:0001437749-24-031909:0
209 shares@ US$1.000.1% of flowCommon Stock, Par Value $0.001SEC:0001437749-24-030125:0
1,000 shares@ US$1.000.4% of flowCommon Stock, Par Value $0.001SEC:0001437749-24-029896:0
112,356 shares@ US$0.897.3% of flowCommon Stock, Par Value $0.001SEC:0001437749-24-028154:0
123,560 shares@ US$0.8941.1% of flowCommon Stock, Par Value $0.001SEC:0001437749-24-028157:0
134,832 shares@ US$0.8917.3% of flowCommon Stock, Par Value $0.001SEC:0001437749-24-028155:0
25 of 98 declarations
About Milestone Scientific Inc.
Milestone Scientific Inc. is a U.S.-based medical technology company listed on NYSE American, part of the NYSE market, under the ticker MLSS. Incorporated in Delaware in August 1989, the company is headquartered in Roseland, New Jersey, United States. Its business is centered on computer-controlled injection and anesthetic delivery technologies designed to improve precision, pressure control, and patient comfort in both medical and dental procedures. ([sec.gov](https://www.sec.gov/Archives/edgar/data/855683/000143774925012050/mlss20241231_10k.htm))
The company’s core platform is its proprietary Dynamic Pressure Sensing (DPS) technology. Milestone has built its product portfolio around devices that aim to deliver injectable anesthetics and other liquids more accurately than conventional manual syringes. In dentistry, its brands include The Wand®, CompuDent®, and the STA Single Tooth Anesthesia System®. In medicine, the flagship platform is CompuFlo®, including the CompuFlo Epidural Computer Controlled Anesthesia System, which the company says can provide real-time visual and audible pressure feedback to help clinicians identify the epidural space with greater objectivity. The company received FDA clearance in June 2017 to market the CompuFlo Epidural System in the United States for epidural injections. ([sec.gov](https://www.sec.gov/Archives/edgar/data/855683/000143774925012050/mlss20241231_10k.htm))
Read moreShow less
Milestone occupies a specialized niche in the broader medical devices market rather than competing as a diversified device manufacturer. Its competitive edge is built on patent protection, a differentiated clinical workflow, and claims around improved accuracy, safety, and patient experience. At the same time, the business faces a demanding regulatory environment, strong competition from larger device makers, and execution risk tied to commercialization, reimbursement, and manufacturing partnerships. The company notes that it sells dental products through a mix of exclusive and non-exclusive distributors worldwide, while medical products are sold internationally through exclusive distributors in markets such as Italy, Switzerland, Greece, Canada, and the Middle East. In the United States, medical products are marketed through a small direct sales team and a distributor partnership. ([sec.gov](https://www.sec.gov/Archives/edgar/data/855683/000143774925012050/mlss20241231_10k.htm))
Recent developments indicate a company in transition. In its March 31, 2026 business update and full-year 2025 results, management said the business had moved from restructuring toward growth, highlighting tighter spending control, a relaunch of CompuFlo commercialization efforts, and the launch of a dental ambassador program pilot. Management also signaled expectations for stronger 2026 revenue momentum and continued progress toward profitability. For equity investors, MLSS remains a micro-cap healthcare story with potentially meaningful upside if adoption improves, but it also carries elevated risk tied to product uptake, reimbursement, and capital discipline. ([nasdaq.com](https://www.nasdaq.com/press-release/milestone-scientific-reports-financial-results-fourth-quarter-and-full-year-2025-2026))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
